Clinical Genomics' circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
A study in Cancer Medicine found that a new blood test is more sensitive than a standard carcinoembryonic antigen test when identifying colorectal cancer recurrence.
Here's what you need to know:
1. The new test, developed by Bridgewater, N.J.-based Clinical Genomics, is a two-gene circulating tumor DNA blood test for post-surgical monitoring of colorectal cancer recurrence.
2. The test measures the presence of BCAT1 and IKZF1 gene methylation, a chemical modification associated with tumor growth.
3. The study found that the two-gene circulating tumor DNA blood test identified twice the number of recurrence cases as carcinoembryonic antigen testing.
"Given that at least 30 percent of patients in remission from CRC following initial treatment will develop recurrence, improved surveillance methods that accurately detect recurrence are essential for improving outcomes for patients," a Clinical Genomics press release said.
More articles on gastroenterology and endoscopy:
Takeda Pharmaceuticals, Koneksa Health to introduce biosensors, wearable technology into clinical studies: 3 notes
AGA awards student research fellowship to UPenn's Rani Richardson: 3 highlights
Women's cancer deaths to increase by 60% through 2030: 5 colorectal cancer findings
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- BioSpine Institute adds Dr. M. Nicholas Perenich: 4 takeaways
- Anthem threatens to leave exchanges, implement double-digit premiums if subsidies end
- Opioid abuse drops when providers check patients' past prescriptions: 4 things to know
- AMA implores Congress to reject amended Republican healthcare bill: 4 notes
- GI leader to know: Dr. James Schnell of Palmetto Digestive Health Specialists